GMP News and Research

RSS

BioDlink fast-tracks global growth with bevacizumab launch in Colombia and Pakistan

BioDlink announced that its self-developed bevacizumab injection biosimilar has received marketing approval from Colombia’s National Institute for Surveillance of Medicines and Foods (INVIMA) and Pakistan’s Drug Regulatory Authority of Pakistan (DRAP).

From BioDlink 8 Sep 2025

BioDlink expands ecosystem alliance to empower biotech innovators worldwide

As BioDlink, a leading global CDMO, affirms its commitment to strategic alliances to support biotech innovation worldwide as it marks 15 years of operations.

From BioDlink 5 Sep 2025

Fentanyl abuse impairs cardiac cell function and contributes to heart rhythm defects

In recent years, fentanyl, a synthetic opioid that is 50 to 100 times stronger than morphine, has been a main contributor to the opioid crisis.

28 Aug 2025

How leadership drives inspection readiness from the top down

Discover how proactive leadership sets the tone for inspection readiness across all levels of an organization.

From DSI, a PLG Company 25 Aug 2025

LabConnect deploys Sapio LIMS across global operations

Sapio Sciences, the science-aware™ lab informatics platform, today announced the full deployment of Sapio LIMS at LabConnect.

From Sapio Sciences 7 Aug 2025

The Microsphere Summit is Back

Attend the 2025 Microsphere Summit to connect with leaders in drug delivery and manufacturing, focusing on particle size control and therapeutic advancements.

From Powder Systems 5 Aug 2025

Elegen and Nutcracker Therapeutics to pilot first fully cell-free manufacturing process for RNA-based personalized cancer therapeutics

Elegen, a global leader in next-generation DNA manufacturing, and Nutcracker Therapeutics, a global leader in next-generation RNA design and manufacturing, today announced the launch of a pilot program to demonstrate the industry's first fully synthetic, cell-free manufacturing platform for RNA-based personalized cancer therapeutics (PCTs).

From Elegen Corporation 15 Jul 2025

Biosynth expands Berlin site with a new commercial bioconjugation suite

Biosynth, a leading developer and supplier of critical raw materials and services for life sciences and diagnostics, is pleased to announce the opening of its expanded GMP bioconjugation facility at its existing Berlin site.

7 Jul 2025

Fidelio Capital partners with Alphalyse to accelerate the global roll-out of LC-MS host cell protein analytics

Alphalyse, a fast-growing Danish specialist contract research organization (CRO) that has developed GMP‑validated liquid‑chromatography mass‑spectrometry (LC‑MS) assays for host‑cell‑protein (HCP) impurity testing in biologic drugs, today announces that Fidelio Capital has acquired a majority stake in the company.

From Alphalyse A/S 2 Jul 2025

Evolving spectrophotometry for modern biopharma workflows

Explore how spectrophotometry is evolving to deliver speed and accuracy in biopharma workflows.

From Thermo Fisher Scientific – Pharmaceutical and Biopharmaceutical Solutions 27 Jun 2025

Scaling B-cell cloning workflows for antibody development

Explore the latest tools that boost speed and accuracy in B-cell cloning processes.

From Cellenion 24 Jun 2025

PDE3 inhibitors show promise in promoting bone growth

Bone growth occurs through the proliferation of specialized cells of the cartilage tissue, known as chondrocytes, on either end of a bone.

17 Jun 2025

Nicotinamide riboside shows promise in treating Werner syndrome symptoms

Werner syndrome (WS) is a rare genetic disorder that causes premature aging and serious complications. In the first clinical trial of its kind, researchers from Japan with the company Niagen Bioscience, investigated the effects of nicotinamide riboside (NR), a vitamin B3 derivative, in patients with WS.

5 Jun 2025

Transforming Lab Workflows with Cell Culture Automation: Insights from Unicorn Biotechnologies at SLAS 2025

Discover how Unicorn Biotechnologies is revolutionizing lab workflows with cell culture automation. Expert insights from startup co-founders Jack and Adam.

From Unicorn Biotechnologies 29 May 2025

Targeting cGAS shows promise for treating cardiac dysfunction after cardiac arrest

Announcing a new article publication for Cardiovascular Innovations and Applications journal. Cardiac dysfunction is a prevalent and serious complication after cardiac arrest (CA), yet limited therapeutic interventions are available.

19 May 2025

Waters integrates Multi-Angle Light Scattering Detectors with empower software for improved biologics quality control and simplified regulatory compliance

Waters Corporation today announced that its Empower™ Software now supports biologics data acquisition and quality control (QC) analysis from Multi-Angle Light Scattering (MALS) and differential Refractive Index (RI) instruments in its Wyatt Technology™ Portfolio.

From Waters Corporation 7 May 2025

Survey reveals low awareness of innovative cancer treatment among Americans

Roswell Park Comprehensive Cancer Center is at the forefront of a new approach to cancer treatment, called CAR T-cell therapy.

17 Apr 2025

Breakthrough in scalable nanoparticle manufacturing for cancer treatment

Polymer-coated nanoparticles loaded with therapeutic drugs show significant promise for cancer treatment, including ovarian cancer.

4 Apr 2025

4basebio receives MHRA GMP licence for manufacture and supply of synthetic DNA

4basebio PLC (“4basebio”), a company which develops and commercializes the large-scale manufacture of synthetic DNA as well as nanoparticle delivery solutions, today announced that it has received Good Manufacturing Practice (GMP) certification from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA).

From 4basebio PLC 3 Apr 2025

BIOVECTRA is honored with 2025 CDMO Leadership Award for biologics

BIOVECTRA, a part of Agilent Technologies Inc., is a leading North American CDMO specializing in biologics, mRNA therapeutics, and complex chemistry, proudly announces it is the recipient of the 2025 Outsourced Pharma CDMO Leadership Award in the category of biologics.

13 Mar 2025